Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites

Inclusion Criteria: * Patients with cirrhosis and refractory ascites who required 3 or more large volume (4 liters and more) paracenteses in the previous 60 days Exclusion Criteria: * Ascites with causes other than cirrhosis such as nephrogenic ascites or malignant ascites due to peritoneal carcinomatosis * Total bilirubin \> 5 mg/dL * Blood clotting International normalized ratio (INR) \> 2.5 * Serum creatinine \> 2.0 mg/dL * Current or recent (within 3 months of consent) renal dialysis * Hepatic encephalopathy grade 3 or 4 * Superimposed acute liver failure/injury due to factors other than alcoholic hepatitis, including acute viral hepatitis, drugs, medications (e.g., acetaminophen), or other toxins (e.g., mushroom \[Amanita\] poisoning) * Current or recent treatment (within 7 days) with octreotide, midodrine, vasopressin, dopamine or other vasopressors * Respiratory failure requiring positive airway pressure devices or intubation * SIRS/sepsis episode in the previous 28 days from consent * Episode of spontaneous bacterial peritonitis or gastrointestinal hemorrhage within 28 days of consent * Ongoing documented or suspected infection * Severe cardiovascular disease that are contraindication to terlipressin therapy such as advanced arteriosclerosis, arrhythmia, coronary insufficiency or uncontrolled hypertension * Findings suggestive of organic renal disease (severe proteinuria/hematuria, or abnormal renal ultrasound suggestive of obstructive or other renal pathology) * Severe comorbidity that in the opinion of the Investigator would affect short-term prognosis and/or disallow safe participation in the trial (such as for example, severe anemia or pancytopenia, advanced neoplasia, hepatocellular carcinoma \[confirmed with serum alpha1-fetoprotein testing\], severe chronic obstructive pulmonary disease or asthma) * Alcoholics who have not been abstinent for the past 6 months * Transjugular intrahepatic portosystemic shunt or other surgical shunt * For female patients: Confirmed pregnancy * Known allergy or hypersensitivity to terlipressin * Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of consent.